GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » Asset Turnover

Inogen (Inogen) Asset Turnover

: 0.23 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Inogen's Revenue for the three months ended in Dec. 2023 was $75.9 Mil. Inogen's Total Assets for the quarter that ended in Dec. 2023 was $334.9 Mil. Therefore, Inogen's Asset Turnover for the quarter that ended in Dec. 2023 was 0.23.

Asset Turnover is linked to ROE % through Du Pont Formula. Inogen's annualized ROE % for the quarter that ended in Dec. 2023 was -48.79%. It is also linked to ROA % through Du Pont Formula. Inogen's annualized ROA % for the quarter that ended in Dec. 2023 was -31.71%.


Inogen Asset Turnover Historical Data

The historical data trend for Inogen's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.68 0.75 0.84 0.86

Inogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.18 0.22 0.23 0.23

Competitive Comparison

For the Medical Devices subindustry, Inogen's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inogen Asset Turnover Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Inogen's Asset Turnover falls into.



Inogen Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Inogen's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=315.66/( (405.041+326.194)/ 2 )
=315.66/365.6175
=0.86

Inogen's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=75.896/( (343.696+326.194)/ 2 )
=75.896/334.945
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Inogen  (NAS:INGN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Inogen's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-106.22/217.721
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-106.22 / 303.584)*(303.584 / 334.945)*(334.945/ 217.721)
=Net Margin %*Asset Turnover*Equity Multiplier
=-34.99 %*0.9064*1.5384
=ROA %*Equity Multiplier
=-31.71 %*1.5384
=-48.79 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Inogen's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-106.22/334.945
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-106.22 / 303.584)*(303.584 / 334.945)
=Net Margin %*Asset Turnover
=-34.99 %*0.9064
=-31.71 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Inogen Asset Turnover Related Terms

Thank you for viewing the detailed overview of Inogen's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Inogen (Inogen) Business Description

Traded in Other Exchanges
Address
301 Coromar Drive, Goleta, CA, USA, 93117
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.
Executives
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer officer: EVP, Chief Medical Officer C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer officer: EVP, Gen. Counsel & Secretary C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King director C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider officer: EVP, CFO and Treasurer C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M director 1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter officer: EVP, CFO and Treasurer 301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger director, officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor officer: Vice President, Engineering 326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora director C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers officer: Vice President, Marketing 326 BOLLAY DRIVE, GOLETA CA 93117